|
1
|
Roschewski M and Wilson WH: EBV-associated
lymphomas in adults. Best Pract Res Clin Haematol. 25:75–89.
2012.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Young LS and Murray PG: Epstein-Barr virus
and oncogenesis: From latent genes to tumours. Oncogene.
22:5108–5121. 2003.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Carbone A, Gloghini A and Dotti G:
EBV-associated lymphoproliferative disorders: Classification and
treatment. Oncologist. 13:577–585. 2008.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Sbih-Lammali F, Djennaoui D, Belaoui H,
Bouguermouh A, Decaussin G and Ooka T: Transcriptional expression
of Epstein-Barr virus genes and proto-oncogenes in north African
nasopharyngeal carcinoma. J Med Virol. 49:7–14. 1996.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Shannon-Lowe C and Rickinson AB: Bell AIL
Epstein-Barr virus-associated lymphomas. Philos Trans R Soc Lond B
Biol Sci. 372(20160271)2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Vockerodt M, Yap LF, Shannon-Lowe C,
Curley H, Wei W, Vrzalikova K and Murray PG: The Epstein-Barr virus
and the pathogenesis of lymphoma. J Pathol. 235:312–322.
2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Dong H, Zhu G, Tamada K and Chen L: B7-H1,
a third member of the B7 family, co-stimulates T-cell proliferation
and interleukin-10 secretion. Nat Med. 5:1365–1369. 1999.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Francisco LM, Sage PT and Sharpe AH: The
PD-1 pathway in tolerance and autoimmunity. Immunol Rev.
236:219–242. 2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Francisco LM, Salinas VH, Brown KE,
Vanguri VK, Freeman GJ, Kuchroo VK and Sharpe AH: PD-L1 regulates
the development, maintenance, and function of induced regulatory T
cells. J Exp Med. 206:3015–3029. 2009.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012.PubMed/NCBI View
Article : Google Scholar
|
|
11
|
Ohaegbulam KC, Assal A, Lazar-Molnar E,
Yao Y and Zang X: Human cancer immunotherapy with antibodies to the
PD-1 and PD-L1 pathway. Trends Mol Med. 21:24–33. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ma G, Deng Y, Jiang H, Li W, Wu Q and Zhou
Q: The prognostic role of programmed cell death-ligand 1 expression
in non-small cell lung cancer patients: An updated meta-analysis.
Clin Chim Acta. 482:101–107. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Abdel-Rahman O: PD-L1 expression and
outcome of advanced melanoma patients treated with anti-PD-1/PD-L1
agents: A meta-analysis. Immunotherapy. 8:1081–1089.
2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wang Z, Peng S, Xie H, Guo L, Cai Q, Shang
Z, Jiang N and Niu Y: Prognostic and clinicopathological
significance of PD-L1 in patients with renal cell carcinoma: A
meta-analysis based on 1863 individuals. Clin Exp Med. 18:165–175.
2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Younes A, Santoro A, Shipp M, Zinzani PL,
Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V,
Kuruvilla J, et al: Nivolumab for classical Hodgkin's lymphoma
after failure of both autologous stem-cell transplantation and
brentuximab vedotin: A multicentre, multicohort, single-arm phase 2
trial. Lancet Oncol. 17:1283–1294. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Muenst S, Hoeller S, Willi N, Dirnhofera S
and Tzankov A: Diagnostic and prognostic utility of PD-1 in B cell
lymphomas. Dis Markers. 29:47–53. 2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ahearne MJ, Bhuller K, Hew R, Ibrahim H,
Naresh K and Wagner SD: Expression of PD-1 (CD279) and FoxP3 in
diffuse large B-cell lymphoma. Virchows Arch. 465:351–358.
2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Tse E and Kwong YL: How I treat NK/T-cell
lymphomas. Blood. 121:4997–5005. 2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ok CY, Papathomas TG, Medeiros LJ and
Young KH: EBV-positive diffuse large B-cell lymphoma of the
elderly. Blood. 122:328–340. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Green MR, Rodig S, Juszczynski P, Ouyang
J, Sinha P, O'Donnell E, Neuberg D and Shipp MA: Constitutive AP-1
activity and EBV infection induce PD-L1 in Hodgkin lymphomas and
posttransplant lymphoproliferative disorders: Implications for
targeted therapy. Clin Cancer Res. 18:1611–1618. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kwon D, Kim S, Kim PJ, Go H, Nam SJ, Paik
JH, Kim YA, Kim TM, Heo DS, Kim CW and Jeon YK: Clinicopathological
analysis of programmed cell death 1 and programmed cell death
ligand 1 expression in the tumour microenvironments of diffuse
large B cell lymphomas. Histopathology. 68:1079–1089.
2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Alaggio R, Amador C, Anagnostopoulos I,
Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D,
Calaminici M, et al: The 5th edition of the world health
organization classification of haematolymphoid tumours: Lymphoid
neoplasms. Leukemia. 36:1720–1748. 2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Mantel N and Haenszel W: Statistical
aspects of the analysis of data from retrospective studies of
disease. J Natl Cancer Inst. 22:719–748. 1959.PubMed/NCBI
|
|
24
|
Kiyasu J, Miyoshi H, Hirata A, Arakawa F,
Ichikawa A, Niino D, Sugita Y, Yufu Y, Choi I, Abe Y, et al:
Expression of programmed cell death ligand 1 is associated with
poor overall survival in patients with diffuse large B-cell
lymphoma. Blood. 126:2193–2201. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Chen BJ, Chapuy B, Ouyang J, Sun HH,
Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA and Rodig
SJ: PD-L1 expression is characteristic of a subset of aggressive
B-cell lymphomas and virus-associated malignancies. Clin Cancer
Res. 19:3462–3473. 2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Anastasiadou E, Stroopinsky D, Alimperti
S, Jiao AL, Pyzer AR, Cippitelli C, Pepe G, Severa M, Rosenblatt J,
Etna MP, et al: Epstein-Barr virus-encoded EBNA2 alters immune
checkpoint PD-L1 expression by downregulating miR-34a in B-cell
lymphomas. Leukemia. 33:132–147. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Kinch A, Sundstrom C, Baecklund E, Backlin
C, Molin D and Enblad G: Expression of PD-1, PD-L1, and PD-L2 in
posttransplant lymphoproliferative disorder after solid organ
transplantation. Leuk Lymphoma. 60:376–384. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Veloza L, Teixido C, Castrejon N, Climent
F, Carrio A, Marginet M, Soldini D, González-Farré B,
Ribera-Cortada I, Lopez-Guillermo A, et al: Clinicopathological
evaluation of the programmed cell death 1 (PD1)/programmed cell
death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative
disorders: Association with Epstein-Barr virus, PD-L1 copy number
alterations, and outcome. Histopathology. 75:799–812.
2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Ishikawa E, Tanaka T, Shimada K, Kohno K,
Satou A, Eladl AE, Sakakibara A, Furukawa K, Funasaka K, Miyahara
R, et al: A prognostic model, including the EBV status of tumor
cells, for primary gastric diffuse large B-cell lymphoma in the
rituximab era. Cancer Med. 7:3510–3520. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Ishikawa E, Kato S, Shimada K, Tanaka T,
Suzuki Y, Satou A, Kohno K, Sakakibara A, Yamamura T, Nakamura M,
et al: Clinicopathological analysis of primary intestinal diffuse
large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and
Epstein-Barr virus on tumor cells. Cancer Med. 7:6051–6063.
2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Quan L, Chen X, Liu A, Zhang Y, Guo X, Yan
S and Liu Y: PD-1 blockade can restore functions of T-cells in
epstein-barr virus-positive diffuse large B-cell lymphoma in vitro.
PLoS One. 10(e0136476)2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Cohen M, Vistarop AG, Huaman F, Narbaitz
M, Metrebian F, De Matteo E, Preciado MV and Chabay PA: Cytotoxic
response against Epstein Barr virus coexists with diffuse large
B-cell lymphoma tolerogenic microenvironment: Clinical features and
survival impact. Sci Rep. 7(10813)2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Sakakibara A, Kohno K, Eladl AE, Klaisuwan
T, Ishikawa E, Suzuki Y, Shimada S, Nakaguro M, Shimoyama Y,
Takahara T, et al: Immunohistochemical assessment of the diagnostic
utility of PD-L1: A preliminary analysis of anti-PD-L1 antibody
(SP142) for lymphoproliferative diseases with tumour and
non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
Histopathology. 72:1156–1163. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Paydas S, Bagir E, Seydaoglu G, Ercolak V
and Ergin M: Programmed death-1 (PD-1), programmed death-ligand 1
(PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.
Ann Hematol. 94:1545–1552. 2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ozturk V, Yikilmaz AS, Kilicarslan A,
Bakanay SM, Akinci S and Dilek I: The triple positivity for EBV,
PD-1, and PD-L1 identifies a very high risk classical hodgkin
lymphoma. Clin Lymphoma Myeloma Leuk. 20:e375–e381. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Antel K, Chetty D, Oosthuizen J, Mohamed
Z, Van der Vyver L and Verburgh E: CD68-positive tumour associated
macrophages, PD-L1 expression, and EBV latent infection in a high
HIV-prevalent South African cohort of Hodgkin lymphoma patients.
Pathology. 53:628–634. 2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kohno K, Suzuki Y, Elsayed AA, Sakakibara
A, Takahara T, Satou A, Kato S, Nakamura S and Asano N:
Immunohistochemical assessment of the diagnostic utility of PD-L1
(Clone SP142) for methotrexate-associated lymphoproliferative
disorders with an emphasis of neoplastic PD-L1 (Clone
SP142)-positive classic hodgkin lymphoma type. Am J Clin Pathol.
153:571–582. 2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Laurent C, Fabiani B, Do C, Tchernonog E,
Cartron G, Gravelle P, Amara N, Malot S, Palisoc MM, Copie-Bergman
C, et al: Immune-checkpoint expression in Epstein-Barr virus
positive and negative plasmablastic lymphoma: A clinical and
pathological study in 82 patients. Haematologica. 101:976–984.
2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Kataoka K, Miyoshi H, Sakata S, Dobashi A,
Couronne L, Kogure Y, Sato Y, Nishida K, Gion Y, Shiraishi Y, et
al: Frequent structural variations involving programmed death
ligands in Epstein-Barr virus-associated lymphomas. Leukemia.
33:1687–1699. 2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Marques-Piubelli ML, Salas YI, Pachas C,
Becker-Hecker R, Vega F and Miranda RN: Epstein-Barr
virus-associated B-cell lymphoproliferative disorders and
lymphomas: A review. Pathology. 52:40–52. 2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Wang BJ, Bao JJ, Wang JZ, Wang Y, Jiang M,
Xing MY, Zhang WG, Qi JY, Roggendorf M, Lu MJ and Yang DL:
Immunostaining of PD-1/PD-Ls in liver tissues of patients with
hepatitis and hepatocellular carcinoma. World J Gastroenterol.
17:3322–3329. 2011.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Badoual C, Hans S, Merillon N, Van Ryswick
C, Ravel P, Benhamouda N, Levionnois E, Nizard M, Si-Mohamed A,
Besnier N, et al: PD-1-expressing tumor-infiltrating T cells are a
favorable prognostic biomarker in HPV-associated head and neck
cancer. Cancer Res. 73:128–138. 2013.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Fang W, Zhang J, Hong S, Zhan J, Chen N,
Qin T, Tang Y, Zhang Y, Kang S, Zhou T, et al: EBV-driven LMP1 and
IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma:
Implications for oncotargeted therapy. Oncotarget. 5:12189–12202.
2014.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Barzyk GA and Sheriff V: EBV positivity
and programmed death-ligand 1 expression in diffuse large B-cell
lymphoma: A systematic review. Anticancer Res. 40:5951–5968.
2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Weniger MA and Küppers R: Molecular
biology of Hodgkin lymphoma. Leukemia. 35:968–981. 2021.PubMed/NCBI View Article : Google Scholar
|
